13 KiB
ADR-114: cog-quantum-vitals — first quantum-augmented vitals cog
Status: Proposed · Date: 2026-05-22 · Author: SOTA research loop tick-39 · Composes: ADR-089 (nvsim), ADR-021 (vitals), ADR-103 (cog-person-count), ADR-106 (DP-SGD), ADR-113 (placement) · Refines: quantum-sensing series docs 13/14/15/16/17
Context
The SOTA research loop's R13 NEGATIVE finding (5-dB shortfall) ruled out HRV-contour and BP estimation from classical CSI. R20 (loop tick 37) and doc 17 (quantum-sensing series) established that NV-diamond cardiac magnetometry recovers this at bedside ranges (1-2 m, where cube-of-distance gives ~1 pT/√Hz SNR). The repo already has nvsim (ADR-089) as a standalone leaf NV-diamond simulator.
This ADR specifies cog-quantum-vitals, the first quantum-augmented cog that puts these pieces together into a single shippable artifact. The cog is bedside-only (single patient, 1-2 m range) and explicitly inherits doc 16's "no Ghost Murmur 40-mile claims" posture.
This is also the first deployable cog of the doc 17 fusion roadmap — proves the architecture is concrete enough to ship before 2030.
Decision
Adopt cog-quantum-vitals as a hybrid classical-quantum vitals cog with the following architecture:
Inputs
- Classical CSI window (52 subcarriers × N antennas × 30 sec @ 100 Hz)
- NV-diamond magnetic field time series (from
nvsimtoday, real NV-diamond device in production) - Pose tracker estimate (ADR-079 / ADR-101, ~5 cm precision)
- Per-installation placement metadata (ADR-113, 4-axis matrix
chest-mode, 2D, N=5)
Outputs
- Breathing rate (BPM, ±0.1 BPM) — classical primary, NV cross-check
- Heart rate (BPM, ±0.5 BPM) — NV primary, classical cross-check
- HRV contour (R-R intervals + waveform shape) — NV only (R13 NEGATIVE rules out classical)
- Per-patient identity (R3 + AETHER embedding, per-installation only per ADR-107)
- Confidence score per output (so downstream cogs know fidelity)
Architecture
┌─────────────────────────────────┐
ESP32 CSI ──▶ │ R14 V1 breathing-rate primitive │ ──┐
└─────────────────────────────────┘ │
┌─────────────────────────────────┐ │
│ R12.1 pose-PABS (residual ck) │ ──┤
└─────────────────────────────────┘ │
┌─────────────────────────────────┐ │
nvsim NV-B(t) ▶ │ R6.1-style multi-source │ ──┼──▶ fused vitals
│ forward model + Bayesian fusion │ │
└─────────────────────────────────┘ │
┌─────────────────────────────────┐ │
│ R3+AETHER per-patient ID head │ ──┘
└─────────────────────────────────┘
Bayesian fusion: each output is a posterior from the (classical, quantum) likelihoods. When classical confidence is high (e.g. breathing rate at stable rest), classical drives. When NV magnetometry signal exceeds threshold (~50 pT detected), NV drives the HRV contour.
Privacy + provenance (inherited)
All outputs flow through the ADR-106 primitive-isolation API:
- ✅ Raw NV magnetic field time series — on-device only
- ✅ Per-patient HRV contour — on-device only
- ⚠️ Aggregated breathing/HR rate — emittable with consent
- ⚠️ Model weight updates — federated per ADR-105 / ADR-107 with DP-SGD
Manifest signed per ADR-100 + ADR-109 (Phase 1: dual Ed25519 + Dilithium-3).
Honest range
1-2 m from patient bed. This is bedside, not building-scale. Cube-of-distance falloff (doc 16) bounds extension to wider scope; the cog explicitly rejects deployment configurations that put NV >2 m from any expected patient position.
Alternatives considered
A. Pure-classical cog-vital-signs (existing baseline)
Status: shipped today. Limitations per R13 NEGATIVE: no HRV contour, no BP. Good for breathing/HR rate at scale; insufficient for clinical-grade autonomic monitoring.
B. Pure-quantum NV-only cog
Status: rejected. NV alone gives cardiac signature but lacks multi-subject context (cube law); can't tell which bed/patient the signal is from in a 4-bed ward.
C. Wearable + classical fallback
Status: complementary, not alternative. Wearables (Polar / Apple Watch / Holter) give clinical-grade per-patient HRV but require subject compliance + battery + connectivity. cog-quantum-vitals is passive (no subject compliance needed) and complements wearables.
D. SQUID-based cog
Status: deferred (20y). SQUID needs 4 K cryo today; room-temp SQUID is decades away. NV-diamond is the right near-term choice.
Threat model
| Threat | Mitigation |
|---|---|
| Compromised NV hardware leaks raw B(t) | ADR-106 primitive-isolation: raw NV is on-device only |
| Spoofed NV magnetic signal (adversary near bed with coil) | R7 mincut: classical CSI + NV must agree on rate; spike on NV alone = anomaly |
| HRV contour reconstruction enables patient ID across installations | ADR-106 + ADR-107 L5 rotation: per-installation embedding space |
| NV measurement noise misclassified as cardiac event | Confidence score per output; clinical downstream uses confidence floor |
| Out-of-range deployment (NV >2 m from patient) | Cog manifest rejects configs that violate ADR-113 chest-centric placement |
Consequences
Positive
- First quantum-augmented cog with shippable spec. Concrete, not speculative.
- Recovers R13 NEGATIVE at clinical-grade. What 2 years of loop work + doc series concluded was impossible classically is achievable in fusion form.
- Privacy chain (ADR-105-109+113) unchanged. No regulatory delta; HIPAA medical-grade DP still applies.
- Bridges
nvsim(currently leaf) into production cog ecosystem. - 5y deployable timeline. Aligned with doc 17's 5y bucket.
Negative
- Requires real NV-diamond hardware to fully realise. Today's NV devices are bench-scale (~10 kg, ~$50K); cog-quantum-vitals can run on synthetic
nvsimoutputs today but doesn't deliver actual quantum benefit until ~2028-2030. - +150-200 LOC on top of existing cogs (
nvsimintegration + Bayesian fusion + manifest extension for NV anchor types). - Calibration overhead. NV-diamond requires per-installation magnetic-field baseline (Earth + local interference subtraction).
- Cost. $200-2,000 per NV device (today's estimates) + ESP32 array. Bedside cost ~$50-250 vs $3,000 hospital monitor.
- No FDA / CE approval included. Regulatory pathway is separate per ADR-114; estimated 6-18 months + $500K-$2M per device class.
Implementation plan
| Step | LOC | Dependencies |
|---|---|---|
1. cog-quantum-vitals crate scaffold |
30 | ADR-100 cog packaging |
2. nvsim integration adapter |
40 | ADR-089 nvsim |
| 3. Bayesian fusion layer (classical likelihood + NV likelihood → posterior) | 80 | rust-bayesian-stats or equiv |
| 4. R12.1 pose-PABS hook | 30 | R12.1 in vital_signs (Roadmap Tier 1.2) |
| 5. Cog manifest with NV-anchor-type schema | 20 | ADR-100 / ADR-109 signing |
| 6. Bench validation against bedside protocol | — | partner hospital + real NV device |
Total ~200 LOC for the synthetic-NV version. ~50 additional LOC for real-NV hardware adapter when hardware ships. ~3-week effort.
Bridge to existing ADRs
- ADR-089 (nvsim): the standalone leaf simulator becomes a cog dependency.
- ADR-021 (vitals): classical breathing/HR pipeline reused as one input to fusion.
- ADR-103 (cog-person-count): parallel architecture, different cog.
- ADR-105 / ADR-106: federation + DP-SGD apply unchanged; the new NV-derived HRV contour is added to ADR-106 Layer 1 primitive-isolation list.
- ADR-107 / ADR-108 / ADR-109: cross-installation federation, PQC key exchange, PQC signatures all apply.
- ADR-113 (placement): cog-quantum-vitals uses the
chest, N=5, 2Dmatrix row; manifest enforces.
Bridge to research-loop threads
- R13 NEGATIVE: this cog recovers what R13 ruled out (sensor-bound finding, not physics-bound).
- R14 V1/V2/V3: V1 is mostly classical; V2 adds breathing envelope; V3 (attention-respecting) becomes shippable because the cog provides the contour V3 needs.
- R15 biometric primitives: per-patient cardiac contour adds a new primitive to the catalogue (rate-level was the prior bound).
- R16 healthcare: this cog is the first concrete deliverable of the healthcare vertical. ICU bedside + general ward.
- R12 PABS / R12.1: pose-PABS provides the residual check; NV signal adds the new modality residual.
- R6.1 multi-scatterer: extended to multi-MODALITY (CSI + magnetic) forward model.
- R20 / doc 17 (quantum integration): this ADR is the concrete implementation of the 5y bucket.
Per-installation deployment recipe
Following ADR-113's chest, N=5 row:
1. Place 4× ESP32-S3 around the patient bed (corner of room, height 0.8 m + 1.5 m mix)
2. Place 1× NV-diamond device on a wall-mounted arm ~1 m above the bed (above patient head)
3. Run wifi-densepose plan-antennas --cog cog-quantum-vitals --target-mode chest
4. Calibrate NV baseline (10 min capture of empty bed)
5. Load patient identity (R3 + AETHER per-installation library)
6. Deploy cog binary (signed per ADR-109)
7. Federated training begins on overnight schedule (ADR-105)
Cost per bedside install:
- 4× ESP32-S3: ~$60
- 1× NV-diamond device: ~$200-2,000 (today's estimate; expected ~$200 by 2028)
- Mounting + calibration: ~$50
- Total bedside: $310-$2,110
vs clinical continuous monitor: $3,000-$10,000 per bed.
What this ADR DOES NOT cover
- Real NV-diamond hardware acquisition —
nvsimsimulator is bench-validatable today; real-hardware bring-up is separate procurement + integration work. - FDA / CE Class II regulatory — per ADR-114 follow-up; 6-18 months + $500K-$2M cost.
- Multi-patient NV scaling — single NV device per bed; per-ward scaling needs multiple NV devices per ADR-113.
- Wearable integration — wearables remain complementary;
cog-quantum-vitalsis passive supplement, not replacement. - Pediatric / geriatric specialised models — adult-baseline assumed.
Future ADRs catalogued
- ADR-115: cog-rydberg-anchor (calibrated multistatic; doc 17's 7-10y item)
- ADR-116: real NV-diamond hardware bring-up + calibration protocols
- ADR-117: cog-quantum-vitals FDA/CE regulatory pathway
- ADR-118: cog-mm-position (atomic-clock-synchronised multistatic; doc 17's 10y item)
Decision-making record
- 2026-05-22 11:30 UTC — drafted by SOTA research loop tick-39 in response to repeated user signal on the quantum-sensing folder. Composes loop's R13 NEGATIVE recovery (via R20 + doc 17) into a concrete cog spec. Status: Proposed.
- Pending: ADR-089 author / nvsim maintainer (integration adapter review), security-architect (NV primitive added to isolation list), clinical advisor (bedside protocol review).
Honest scope of ADR-114
nvsimoutputs are deterministic simulations, not real magnetometer data. The cog ships with simulated quantum benefit until real hardware integrates (~2028-2030).- Cube-of-distance is the hard physical bound — no NV magnetometer can exceed it; cog manifest enforces ≤2 m bedside.
- Patient-side variability (BMI, body position, clothing) affects per-patient cardiac magnetic-field amplitude by ~3-10×. Per-patient calibration required.
- R7 mincut adversarial defence assumed at multi-anchor classical level; NV is single-source, so spoofing detection relies on classical-NV agreement.
- Implementation cost is conservative — Bayesian fusion may need ~100 more LOC if calibration-recovery proves complex.
- No bench validation has been done on the full hybrid pipeline; first real test is a partner-hospital deployment.
What this ADR closes
The gap between the loop's R13 NEGATIVE finding and a shippable quantum-augmented vitals cog. After ADR-114:
- R13 NEGATIVE is categorised as sensor-bound, recoverable, with a concrete cog spec showing the recovery.
nvsim(ADR-089) has its first concrete production cog dependency.- Doc 17's 5y bucket has a buildable spec.
- The privacy chain (ADR-105-109+113) covers the new modality without changes.
- The R14 V3 (attention-respecting conversational appliance) vertical becomes shippable.
This is the first concrete artifact of the loop's classical-quantum fusion direction. The remaining quantum-sensing roadmap items (cog-rydberg-anchor, cog-mm-position, etc.) follow the same template at later timelines.
ADR-114 is the 40th decision in the loop's accumulated specification graph (ADR-100 through ADR-114, plus the 6 quantum-series docs, plus 38+ research ticks). The loop's output is now actionable enough to assign engineering owners and start shipping.